Researchers from Buck Institute for Research on Aging, Brigham Young University and University of Southern California awarded early access to Nautilus’ single-molecule protein analysis platform

SEATTLE — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced the selection of three research proposals submitted to the First Access Challenge, a competition for furthering high-impact work in proteomics. The winning projects were also revealed at the US HUPO (Human Proteome Organization) 2023 Conference in Chicago, IL.

“We congratulate each of the winners and look forward to the biomedical and life sciences advances that our collaborations may enable,” said Parag Mallick, Ph.D., co-founder and Chief Scientist of Nautilus. “The response from researchers across the globe to this First Access Challenge has been incredibly rewarding. It has unlocked the type of creativity we hoped to see when we offered them the chance to apply Nautilus’ novel platform to analyze their samples. These remarkable researchers understand how important single-molecule, intact protein analysis – and the resulting sensitivity and dynamic range that our platform is designed to deliver – will be to their explorations of the proteome.”

Chosen from dozens of entries by scientists across a broad spectrum of disciplines, the three projects expect to gain early access to single-molecule proteomic data through Nautilus’ platform to apply to their areas of research:

• Therapeutics for Acute Kidney Injuries: Joanna Bons, Ph.D., and Jordan Burton, Ph.D., Postdoctoral Research Scientists in the Schilling Lab at the Buck Institute for Research on Aging, will use Nautilus’ Proteome Analysis Platform to investigate total proteome remodeling in acute kidney injuries (AKI) of ischemic-reperfusion injury (IRI) and cisplatin-AKI to identify potential biomarkers or therapeutic targets.
• Pathology of Pulmonary Fibrosis: Samuel Payne, Ph.D., Associate Professor at Brigham Young University, will apply Nautilus’ Protein Identification by Short Epitope Mapping (PrISM) approach to analyzing a three-dimensional lung alveolar organoid model to better understand the systems biology of organoids, their comparison to real tissue and potential application to the pathology of human diseases.
• Cancer Therapies for Glioma: Nicholas Graham, Ph.D., Associate Professor at the University of Southern California, will use Nautilus’ platform to identify protein biomarkers of sensitivity to arginine deprivation-induced cancer cell death, aiming to enable a deeper understanding of metabolic vulnerabilities in glioma, an aggressive brain tumor.

The research teams will work with Nautilus’ scientists to conduct a quantitative, single-molecule analysis of 12 samples, as well as receive a conference travel stipend to present the data and writing assistance for a peer-reviewed journal submission.

About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle and its research and development headquarters in the San Francisco Bay Area, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.

Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus’ expectations regarding the company’s business operations expectations with respect to the suitability of the Nautilus product platform to investigate proteins and proteoforms; expectations with respect to the functionality and performance of Nautilus’ product platform, and its ability to advance biological research and its potential impact on pharmaceutical development and drug discovery. These statements are based on numerous assumptions concerning the development of Nautilus’ products and target markets and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus’ assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: Nautilus’ product platform is not yet commercially available and remains subject to significant scientific and technical development, which is inherently challenging and difficult to predict, particularly with respect to highly novel and complex products such as those being developed by Nautilus. Even if our development efforts are successful, our product platform will require substantial validation of its functionality and utility in life science research. In the course of Nautilus’ scientific and technical development and associated product validation and commercialization, we may experience material delays as a result of unanticipated events. We cannot provide any guarantee or assurance with respect to the outcome of our development, collaboration, and commercialization initiatives or with respect to their associated timelines. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information in our Annual Report on Form 10-K filed for the year ended December 31, 2022. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Disclosure Information
Nautilus uses filings with the Securities and Exchange Commission, its website (www.nautilus.bio), press releases, public conference calls, public webcasts, and its social media accounts as means of disclosing material non-public information and for complying with Regulation FD. Therefore, Nautilus encourages investors, the media, and others interested in Nautilus to review the information it makes public in these locations, as such information could be deemed to be material information.

Media Contact
[email protected]

Investor Contact
[email protected]